Recruiting studies: Extensive Stage Small Cell Lung Cancer Es Sclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cel
Phase 3 · 218 location(s) · Gilead Sciences · NCT06801834 Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NA · 1 location(s) · Ruijin Hospital · NCT05552846 Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT06217757 Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cel
Phase N/A · 1 location(s) · Shanghai Chest Hospital of Shanghai Jiao Tong University · NCT07070011 Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2 · 5 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07061535 Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07110103 PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06429696 Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Phase 2 · 6 location(s) · Second Hospital of Shanxi Medical University · NCT06536868 Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT07244016 First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Phase 2 · 1 location(s) · Xiaorong Dong · NCT05745350 A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · 242 location(s) · Boehringer Ingelheim · NCT07472517 Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Phase 2 · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06739928 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · 148 location(s) · SWOG Cancer Research Network · NCT06769126 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated S
Phase 3 · 221 location(s) · BioNTech SE · NCT06712355 A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combinati
Phase 2 · 61 location(s) · AbbVie · NCT07155174 Liposomal Irinotecan and Apatinib in ES-SCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06749691 Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of E
Phase 2 · 1 location(s) · Chongqing University Cancer Hospital · NCT07425795 Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Phase 2 · 1 location(s) · Anhui Provincial Cancer Hospital · NCT06838208 Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Phase 2 · 25 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06663098 A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in
Phase 1/Phase 2 · 58 location(s) · Daiichi Sankyo · NCT06362252 A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizum
Phase 1 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT07413042 Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4 · 1 location(s) · Pharmacosmos A/S · NCT05874401 Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Phase 1/Phase 2 · 17 location(s) · Genprex, Inc. · NCT05703971 A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Phase 1/Phase 2 · 4 location(s) · Novartis Pharmaceuticals · NCT07564401 A Study of Ivonescimab in First-Line ES-SCLC
Phase 2 · 3 location(s) · Akeso · NCT07245446 Talazoparib and Thoracic RT for ES-SCLC
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT04170946 Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
Phase 2 · 12 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT05623319 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Phase 2 · 4 location(s) · Jazz Pharmaceuticals · NCT07459634 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi
Phase 3 · 164 location(s) · Amgen · NCT07005128

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.